Breaking News

OsoBio Appoints Manufacturing Director

March 31, 2014

Buck brings 20 years of project management experience

Catherine R. Buck has been appointed director of manufacturing at OsoBio. Ms. Buck is responsible for ensuring operations comply with cGMP as they apply to the manufacture of injectable sterile liquid, suspension and lyophilized pharmaceutical products. Additionally, she will ensure compliance with appropriate FDA regulations, and direct manufacturing activities.
Ms. Buck has more than 20 years of leadership and project management experience within the pharmaceutical, medical device and construction industries, and has managed multiple commercial and clinical pharmaceutical manufacturing plants. Her experience includes the start up, process, equipment and facility validation of a new Amgen manufacturing plant that produced Epogen, as well as obtaining FDA approval of automated equipment and software, and preparing for inspection. Ms. Buck also has managed manufacturing facility operations for Johnson & Johnson and Siemens.
“The same continuous improvement expectations that bear on just about every aspect of industrial productivity exist within pharmaceutical manufacturing as well,” said Milton Boyer, president of OsoBio. “We are fortunate to add someone with Catherine’s breadth of experience to lead a manufacturing team that keeps OsoBio competitive without sacrificing our commitment to quality and cGMP compliance.”

Related Compliance:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks